Abcam, the Cambridge based online antibody supplier, announced that the final results to June 2011 are anticipated to show adjusted pre-tax profit slightly ahead of market expectations. The company's broker forecast sales of £82.9 million and PBT of £32.3 million.
Tight cost control together with the impact of exchange rates has enabled both gross and operating margins (before MitoSciences acquisition costs) to improve over those reported for H1. More cautious spending amongst academic researchers in the US (thought to be due to uncertainty caused by central government negotiations around setting the National Institutes of Health budget) resulted in a reduced rate of US sales growth in H2, but some recovery has been seen in recent months.
Abcam's catalogue has grown to over 73,652 products (2010: 63,010).
The ABC share price has increased by 45% over the past year.
Abcam Plc is graded B by LCF Research. To learn more, follow the link.
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.